| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9aa83cbc9899a23558f8614e2d537eac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2012-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd2cf526dbd0e6ac6fae0891bdbd6527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcff016f4b2992692fdca13c09571d83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db4f160c9d0725dcb512b8d056e047fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_745f10ebddb72ce40ecf87a8aa01125c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_921690112b3c55040122ec8025f51632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b52a536b46a4d14444490875b20a27c4 |
| publicationDate |
2014-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2760465-A1 |
| titleOfInvention |
Compositions and methods for the treatment of degenerative retinal conditions |
| abstract |
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal- neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation. |
| priorityDate |
2011-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |